Ardelyx Reports Q1 2026 Earnings and Business Update
Ardelyx (ARDX) reported strong first-quarter performance in 2026 with a 58% year-over-year revenue growth for Ibsrela. The company emphasized its strategic priorities, including accelerating the growth of Ibsrela, maintaining momentum with Exposa, expanding its pipeline, and delivering financial results.
Tickers: $ARDX
Topics: commercial_strategy earnings pharmaceuticals pipeline revenue_growth